SNSE logoSNSE
Sensei Biotherapeutics Inc

1,148
Loading...
Loading...
News
all
press releases
Sensei Biotherapeutics: Peer-reviewed research paper on SNS-101 published
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·1y ago
News Placeholder
More News
News Placeholder
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment
BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation...
Globe Newswire·1y ago
News Placeholder
Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Globe Newswire·1y ago
News Placeholder
Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Globe Newswire·2y ago
News Placeholder
Sensei Biotherapeutics reports FY results
Sensei Biotherapeutics reports FY results...
SeekingAlpha.com: All News·2y ago
News Placeholder
Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade...
Globe Newswire·2y ago
News Placeholder
Sensei Biotherapeutics (NASDAQ:SNSE) Shares Down 3.1%
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE Get Free Report)s stock price dropped 3.1% during mid-day trading on Tuesday . The stock traded as low as $0.79 and last traded at $0.79...
Zolmax·2y ago
News Placeholder
Sensei Biotherapeutics to Present at Upcoming Conferences
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation...
Globe Newswire·2y ago
News Placeholder
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 3.8%
Shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE Get Free Report) dropped 3.8% during mid-day trading on Monday . The stock traded as low as $0.76 and last traded at $0.76. Approximately...
Zolmax·2y ago
News Placeholder
Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in...
Globe Newswire·2y ago

Latest SNSE News

View

Advertisement. Remove ads.

Advertisement. Remove ads.